SEC Comment Letter for Viskase Holdings, (VISK) — Sep 8, 2020
Viskase Holdings, Inc.
Date: Sept. 8, 2020 · CIK: 0000727510 · Accession: 0000000000-20-008418
AI Filing Summary & Sentiment
File numbers found in text: 333-248528
Letter
United States securities and exchange commission logo September 8, 2020 Andrew Rackear Chief Executive Officer ENZON PHARMACEUTICALS, INC. 20 Commerce Drive (Suite 135) Cranford, New Jersey 07016 Re:ENZON PHARMACEUTICALS, INC. Registration Statement on Form S-1 Filed September 1, 2020 File No. 333-248528 Dear Mr. Rackear: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Margaret Schwartz at 202-551-7153 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Todd E. Mason
Show Raw Text
United States securities and exchange commission logo
September 8, 2020
Andrew Rackear
Chief Executive Officer
ENZON PHARMACEUTICALS, INC.
20 Commerce Drive (Suite 135)
Cranford, New Jersey 07016
Re:ENZON PHARMACEUTICALS, INC.
Registration Statement on Form S-1
Filed September 1, 2020
File No. 333-248528
Dear Mr. Rackear:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Margaret Schwartz at 202-551-7153 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Todd E. Mason